title: Ritodrine-induced leukocytoclastic vasculitis in pregnancy.
abstract: OBJECTIVE
  To report 2 cases of pregnant women who presented with leukocytoclastic vasculitis (LV) associated with the administration of ritodrine hydrochloride after undergoing genetic amniocentesis and to review the literature on LV. case summaries: Case 1. A 40-year-old pregnant woman was diagnosed with autoimmune hypothyroidism at week 12 of her third gestation. At week 14, she underwent a genetic amniocentesis and received oral prophylactic treatment with ritodrine for 10 days. At week 16, she presented with fever, epigastric abdominal pain, polyarthritis, microhematuria, and purpura. Skin biopsy showed LV. Case 2. A 34-year-old pregnant woman had developed polyarthralgias and polyarthritis after receiving ritodrine following genetic amniocentesis in her second gestation. She also underwent a genetic amniocentesis in her third gestation and received ritodrine. Five days later, she presented with fever, polyarthritis, and purpura. A skin biopsy demonstrated LV. The rest of her gestation was normal until week 33, when she developed oligohydramnios and a delay of intrauterine fetal growth. A cesarean section was then performed. After birth, the baby developed tachypnea, anemia, splenomegaly, edema, and renal failure; she died on her 15th day of life.
  
  
  CONCLUSIONS
  Ritodrine hydrochloride is a beta(2)-adrenergic agonist that is used in pregnant women as a tocolytic agent. In our 2 patients, there was a time relationship between the administration of ritodrine and the appearance of LV. In both cases, other causes of vasculitis were excluded in a reasonable way. As of November 4, 2003, only one other case has been found in the literature. An objective causality assessment revealed that the reactions to ritodrine were probable and possible, respectively, in our 2 cases.
  
  
  CONCLUSIONS
  In pregnant women with autoimmune disease, ritodrine should be used with caution because of its ability to induce vasculitis.
authors.affiliation: Unit of Rheumatology, Obispo Polanco General Hospital, Teruel, Spain. jccobeta@hotmail.com
authors.forename: Juan C
authors.initials: JC
authors.lastname: Cobeta-García
authors.forename: Pilar
authors.initials: P
authors.lastname: García-Enguita
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Pina-Latorre
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Lerin-Sánchez
authors.forename: Francisco
authors.initials: F
authors.lastname: Rodilla-Calvelo
mesh_terms: D000082:Acetaminophen / Q000494:pharmacology / Q000627:therapeutic use; D000284:Administration, Oral; D000328:Adult; D000649:Amniocentesis; D005260:Female; D006801:Humans; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D012312:Ritodrine / Q000008:administration & dosage / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D013997:Time Factors; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000082:Acetaminophen; D012312:Ritodrine; D011241:Prednisone